no worries on the competition

We are very familiar with the capabilities and competitive attributes of Transdermal Technologies. From a competitive standpoint, their core intellectual property post-dates ours and their forskolin penetration enhancer is not inert (i.e. it has pharmacological properties which is not ideal for a chemical penetration enhancer). These points and the small size of Transdermal Technologies position them as a weak competitor to our MDTS(R) technology in our view.

Regards
Tim Morgan, PhD PMP
Director, Business Development
Acrux Limited